Goldman Sachs’s Verona Pharma VRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-1,935,278
| Closed | -$207M | – | 6845 |
|
|
2025
Q3 | $207M | Sell |
1,935,278
-682,019
| -26% | -$71.2M | 0.03% | 593 |
|
|
2025
Q2 | $248M | Buy |
2,617,297
+1,575,889
| +151% | +$117M | 0.03% | 494 |
|
|
2025
Q1 | $66.1M | Buy |
1,041,408
+763,353
| +275% | +$45.7M | 0.01% | 1043 |
|
|
2024
Q4 | $12.9M | Buy |
278,055
+245,166
| +745% | +$9.2M | ﹤0.01% | 2557 |
|
|
2024
Q3 | $946K | Sell |
32,889
-93,684
| -74% | -$2.31M | ﹤0.01% | 4670 |
|
|
2024
Q2 | $1.83M | Buy |
126,573
+33,793
| +36% | +$493K | ﹤0.01% | 3985 |
|
|
2024
Q1 | $1.49M | Buy |
92,780
+52,713
| +132% | +$912K | ﹤0.01% | 4071 |
|
|
2023
Q4 | $797K | Buy |
40,067
+14,668
| +58% | +$217K | ﹤0.01% | 4511 |
|
|
2023
Q3 | $414K | Buy |
25,399
+3,453
| +16% | +$66.5K | ﹤0.01% | 4739 |
|
|
2023
Q2 | $464K | Buy |
21,946
+1,521
| +7% | +$32.4K | ﹤0.01% | 4789 |
|
|
2023
Q1 | $410K | Buy |
20,425
+2,577
| +14% | +$55.6K | ﹤0.01% | 4941 |
|
|
2022
Q4 | $466K | Sell |
17,848
-18,512
| -51% | -$247K | ﹤0.01% | 4904 |
|
|
2022
Q3 | $372K | Buy |
36,360
+24,767
| +214% | +$209K | ﹤0.01% | 5170 |
|
|
2022
Q2 | $49K | Buy |
+11,593
| New | +$49.6K | ﹤0.01% | 6030 |
|
Other funds holding VRNA
Goldman Sachs's VRNA Position: Q4 2025 in Review
Goldman Sachs sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 1,935,278 shares — an estimated $207M sold.
Goldman Sachs first reported a position in VRNA in Q2 2022 and held it in 14 quarters. The position peaked at $248M in Q2 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.
- Goldman Sachs reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
- Goldman Sachs sold 1,935,278 Verona Pharma shares in Q4 2025, an estimated $207M.
- Goldman Sachs first reported a position in Verona Pharma in Q2 2022 and held it in 14 quarters.
- Goldman Sachs's Verona Pharma position peaked at $248M in Q2 2025.
- 1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.
Based on Goldman Sachs's 13F filing for Q4 2025, filed 10 Feb 2026.